IN VITRO EFFECTS OF GROWTH FACTORS AND INTERFERON-α ON BUSULFAN CYTOTOXICITY

REFERENCES

• te Boekhorst P A, Lowenberg B, Vlastuin M, Sonneveld P. Enhanced chemosensitivity of clonogenic blasts from patients with acute myeloid leukemia by G-CSF, IL-3 or GM-CSF stimulation. Leukemia 1993; 7: 1191–1198
   PubMed Web of Science ®Google Scholar
• Vellenga E, Ostapovicz D, O'Rourke B, Griffin J D. Effect of recombinant IL-3, GM-CSF and G-CSF on proliferation of leukemic clonogenic cells in short-term and long-term cultures. Leukemia 1987; 1: 584–589
   PubMed Web of Science ®Google Scholar
• Norgaard J M, Langkjer S T, Ellegaard J, Palshof T, Clausen N, Hokland P. Synergistic and antagonistic effects of myeloid growth factors on in vitro cellular killing by cytotoxic drugs. Leuk Res 1993; 17: 689–694
   PubMedGoogle Scholar
• Zucco H, De Angelis I., Testai E, Stammati A. Toxicology investigations with cell culture systems: 20 years after. Toxicol in Vitro 2004; 18: 153–163
   PubMed Web of Science ®Google Scholar
• Lowenberg B, Tauw I P. Hematopoietic growth factor and their receptors in acute leukemia. Blood 1993; 81: 281–292
   PubMed Web of Science ®Google Scholar
• Rizk E A, El-Gendy W M, Hassab H, El-Madboully L. Granulocyte-macrophage colony-stimulating factor (GM-CSF) in children with acute immune thrombocytopenic purpura. Med Sci Monit 2004; 10: CR330–CR335
   PubMedGoogle Scholar
• Holley R W. Control of growth of mammalian cells in cell culture. Nature 1975; 258: 487–490
   PubMed Web of Science ®Google Scholar
• Sporn M B, Todaro G J. Autocrine secretion and malignant transformation of cells. N Engl J Med 1980; 303: 878–880
   PubMed Web of Science ®Google Scholar
• Michaeli J, Fibach E, Rachmilewitz E A. Induction of differentiation of myeloid leukemic cells by busulphan: in vivo and in vitro observations. Leuk Lymphoma 1993; 11: 287–291
   PubMed Web of Science ®Google Scholar
• Sjoo F, Aschan J, Barkholt L, Hassan Z, Ringden O, Hassan M. N-acetyl-l-cysteine does not affect the pharmacokinetics or myelosuppressive effect of busulfan during conditioning prior to allogeneic stem cell transplantation. Bone Marrow Transplant 2003; 32: 349–354
   PubMed Web of Science ®Google Scholar
• Dressel D, Ritter C A, Sperker B. Busulfan induces activinA expression in vitro and in vivo: a possible link to venous acclusive disease. Clin Pharmacol Ther 2003; 74: 264–274
   PubMedGoogle Scholar
• Bolin R W, Robinson W A, Sutherland J, Hamman R F. Busulfan versus hydroxyurea in long-term therapy of chronic myelogenous leukemia. Cancer 1982; 50: 1683–1686
   PubMed Web of Science ®Google Scholar
• Bouligand J, Boland I, Valteau-Couanet et al. children and adolescents, the pharmacodynamics of high-dose busulfan is dependent on the second alkylating agent used in the combined regimen (melphalan or thiotepa). Bone Marrow Transplant 2003; 32: 979–986
   PubMed Web of Science ®Google Scholar
• Volpe D A, Warren M K. Myeloid clonogenic assays for comparison of the in vitro toxicity of alkylating agents. Toxicol in Vitro 2003; 17: 271–277
   PubMed Web of Science ®Google Scholar
• Pane F, Mostarda I, Selleri C. BCR/ABL mRNA and the P210 (BCR/ABL) protein are downmodulated by interferon-alpha in chronic myeloid leukemia patients. Blood 1999; 94: 2200–2207
   PubMed Web of Science ®Google Scholar
• Grebenova D, Kuzelova K, Fuchs O. Interferon-alpha suppresses proliferation of chronic myelogenous leukemia cells K562 by extending cell cycle S-phase without inducing apoptosis. Blood Cells Mol Dis 2004; 32: 262–269
   PubMedGoogle Scholar
• Archimbaud E, Michallet M, Philip I. Granulocyte colony-stimulating factor given in addition to interferon-alpha to mobilize peripheral blood stem cells for autologous transplantation in chronic myeloid leukaemia. Br J Haematol 1997; 99: 678–684
   PubMed Web of Science ®Google Scholar
• Puntous M, Lacombe F, Dumain P. Treatment of relapsed acute myeloid leukemia using GM-CSF before intensive chemotherapy. Leuk Lymphoma 1993; 12: 95–102
   PubMed Web of Science ®Google Scholar
• Klein E, Ben-Bassat H, Neumann H. Properties of the K562 cell line, derived from a patient with chronic myeloid leukemia. Int J Cancer 1976; 15, 18: 421–431
   Google Scholar
• Fang G, Kim C N, Perkins C L. CGP57148B (STI-571) induces differentiation and apoptosis and sensitises Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs. Blood 2000; 96: 2246–2253
   PubMed Web of Science ®Google Scholar
• Saotome K, Merita H, Umeda M. Cytotoxicity test with simplified crystal violet staining method using microtitre plates and its application to injection drugs. Toxicol in Vitro 1989; 3: 317–321
   PubMed Web of Science ®Google Scholar
• Lange B J. Growth of human leukaemia cells in vitro. Cell Growth and Division: A Practical Approach, R Baserga. IRL Press. 1990
   Google Scholar
• Tsavaris N, Kosmas C, Gouveris P. G-CSF in solid tumor chemotherapy: a tailored regimen reduced febrile neutropenia, treatment delays and direct costs. Med Sci Monit 2004; 10: P124–P128
   Google Scholar
• Yamada G, Kitamura Y, Sonoda H. Retroviral expression of the human IL-2 gene in a murine T cell line results in cell growth autonomy and tumorigenicity. EMBO J 1987; 6: 2705–2709
   PubMed Web of Science ®Google Scholar
• Karasuyama H, Tohyama N, Tada T. Autocrine growth and tumorigenicity of interleukin 2-dependent helper T cells transfected with IL-2 gene. J Exp Med 1989; 169: 13–25
   PubMed Web of Science ®Google Scholar
• Sundman-Engberg B, Paul C, Tidefelt U. Effect of cytokines on the toxicity of cytostatic drugs to normal bone marrow cells in vitro. Cancer Chemother Pharmacol 1998; 42: 255–260
   PubMed Web of Science ®Google Scholar
• Takauji R, Tohyama K, Ueda T, Nakamura T. Enhancement of cytosine arabinoside cytotoxicity by granulacyte/macrophage colony-stimulating factor in a human myeloblastic leukemia cell line. Jpn J Cancer Res 1993; 84: 445–450
   PubMedGoogle Scholar
• Cannistra S A, Groshek P, Griffin J D. Granulocyte-macrophage colony-stimulating factor enhances the cytotoxic effects of cytosine arabinoside in acute myeloblastic leukemia and in the myeloid blast crisis phase of chronic myeloid leukemia. Leukemia 1989; 3: 328–334
   PubMed Web of Science ®Google Scholar
• Luczynski W, Muszynska-Rosian K, Krawczuk-Rybak M, Kuzmicz M, Iwaszkiewicz-Pawlowska A, Kallszewski J. Results of IDA-FLAG programme in the treatment of recurrent acute myeloblastic leukaemia–preliminary report. Med Sci Monit 2001; 7: 125–129
   PubMedGoogle Scholar
• Lemoli R M, Fortuna A, Tafuri A. Interleukin-9 in human myeloid leukemia cells. Leuk Lymphoma 1997; 26: 563–573
   PubMed Web of Science ®Google Scholar
• Lacombe F, Puntous M, Dumain P. Influence of rhGM-CSF on Ara-C sensitivity of patients with acute myeloid leukemia in relapse: a flow cytometry study. Leuk Res 1996; 20: 481–489
   PubMedGoogle Scholar
• Tafuri A, Andreeff M. Kinetic rationale for cytokine-induced recruitment of myeloblastic leukemia followed by cycle-specific chemotherapy in vitro. Leukemia 1990; 4: 826–834
   PubMed Web of Science ®Google Scholar
• Lotem J, Sachs L. Regulation of bcl-2, bcl-XL and bax in the control of apoptosis by hematopoietic cytokines and dexamethasone. Cell Gowth Differ 1995; 6: 647–653
   PubMedGoogle Scholar
• Shabo Y, Lotem J, Sachs L. Induction of genes for transcription factors by normal hematopoietic regulatory proteins in the differentiation of leukemic cells. Leukemia 1990; 4: 797–801
   PubMedGoogle Scholar
• Liu W M, Powles T, Shamash J, Propper D, Oliver T, Joel S. Effect of haemopoietic growth factors on cancer cell lines and their role in chemosensitivity. Oncogene 2004; 29;23: 981–990
   Google Scholar